Munich - March 13, 2015
Press Release
GABO:mi collaborates in regenerative medicine project
funded by the European Commission’s Horizon 2020
programme
March 13, 2015 – The project TREGeneration comprises a European
consortium that recently obtained funding from the European
Commission under the Horizon 2020 programme. The consortium
carries out a clinical research project for the treatment of Graft versus
Host Disease, a serious complication following bone marrow
transplantation. A total of 6 million euros was awarded to the
consortium to perform a 5-year research project which includes a set of
five parallel clinical trials.
Graft versus host disease can be a severe condition occurring when the
donor’s immune cells "attack" the tissues of the patient (skin, internal
organs and mucosa). This disease occurs in about 30 to 50% of patients
undergoing bone marrow transplantation. TREGeneration aims to test a
cell-based therapeutic approach, expected to result in fewer side effects
than the pharmacological strategies currently available.
In each trial, patients will be treated with a particular blood cell
population obtained from the original bone marrow donor. These cells
have the capacity to suppress (regulatory T cells). These are Phase I/II
clinical trials that aim to identify the safe dose to be administered and to
generate preliminary efficacy data.
The Consortium
The TREGeneration consortium is led by João Lacerda’s team at Instituto
de Medicina Molecular in Lisbon, Portugal. GABO:mi, based in Munich, is
in charge of the project management.
The clinical trials will be independently run by each center: Hospital de
Santa Maria in Lisbon, Portugal; Universitaetsklinik in Regensburg,
Germany; Laboratory of Cell and Gene Therapy in Liège, Belgium;
University Hospital S. Orsola-Malpighi in Bologna, Italy.
The consortium further includes a team at the Max Planck Institute for
Molecular Genetics and Alacris Theranostics GmbH. Both are from
Berlin, Germany. The data generated by the different clinical trials will
be integrated by the statistical analysis performed by the Department of
Biostatistics, University of Liverpool, UK.
GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG
Oskar-von-Miller-Ring 29 – 80333 Munich – Germany – phone +49-89-288104-0 – www.gabo-mi.com
Page 1 of 2
Munich - March 13, 2015
Press Release
About Horizon 2020 Programme
Horizon 2020 is the biggest EU Research and Innovation programme ever with
nearly €80 billion of funding available over 7 years (2014 to 2020). It promises
more breakthroughs, discoveries and world-firsts by taking great ideas from the
lab to the market.
About GABO:mi
GABO:mi is a project management company specialised in the management of
EU-funded research projects. Since it was founded in 2005, GABO:mi has
continually expanded its extensive expertise with diverse EU funding
instruments. GABO:mi has managed 40+ medium- and large-scale collaborative
projects funded by the European Commission to date.
Our project managers have vast and valuable experience in the management of
EU-funded projects. They are familiar with the underlying structures of
international collaborative research projects and their governing principles.
Additionally, they are always up-to-date with regard to the current regulations
of the European Commission and its agencies.
Project Logo
Press Contact
GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG
Dr. Sibylle Freitag
Phone: +49-89 288104-18
E-Mail: sibylle.freitag@gabo-mi.com
www.gabo-mi.com
Social Media
Twitter
http://bit.ly/GABOmi_Twitter
GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG
Oskar-von-Miller-Ring 29 – 80333 Munich – Germany – phone +49-89-288104-0 – www.gabo-mi.com
Page 2 of 2